Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities
Authors
Keywords
-
Journal
Immunotherapy
Volume 7, Issue 8, Pages 883-882
Publisher
Future Medicine Ltd
Online
2015-08-28
DOI
10.2217/imt.15.56
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
- (2015) Pradeep M. Nair et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
- (2014) Jonathan D. Graves et al. CANCER CELL
- Cytotoxic Cells Kill Intracellular Bacteria through Granulysin-Mediated Delivery of Granzymes
- (2014) Michael Walch et al. CELL
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Killing Me Softly—Future Challenges in Apoptosis Research
- (2014) Mike-Andrew Westhoff et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Extranodal T-cell/Histiocyte-rich Large B-cell Lymphoma Presenting Primarily on the Skin
- (2013) Y Kambayashi et al. ACTA DERMATO-VENEREOLOGICA
- Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors
- (2013) Adriana Aporta et al. BIOCHEMICAL PHARMACOLOGY
- Death receptors as targets in cancer
- (2013) O Micheau et al. BRITISH JOURNAL OF PHARMACOLOGY
- Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
- (2013) K Azijli et al. CELL DEATH AND DIFFERENTIATION
- Death receptor agonist therapies for cancer, which is the right TRAIL?
- (2013) Pamela M. Holland CYTOKINE & GROWTH FACTOR REVIEWS
- Immunomodulatory Effects of Interferons in Malignancies
- (2013) Joseph Bekisz et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
- (2013) Diego De Miguel et al. MOLECULAR PHARMACEUTICS
- Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
- (2013) H. Walczak Cold Spring Harbor Perspectives in Biology
- Caspase Functions in Cell Death and Disease
- (2013) D. R. McIlwain et al. Cold Spring Harbor Perspectives in Biology
- Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer
- (2012) Luis Martinez-Lostao et al. BIOCHEMICAL PHARMACOLOGY
- Translating TRAIL-receptor targeting agents to the clinic
- (2012) Martha W. den Hollander et al. CANCER LETTERS
- Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis
- (2012) Simone Fulda EXPERIMENTAL CELL RESEARCH
- A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres
- (2012) Hyemin Kim et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies
- (2012) C. T. Hellwig et al. MOLECULAR CANCER THERAPEUTICS
- A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death
- (2012) Laura S. Dickens et al. MOLECULAR CELL
- TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo
- (2012) Benny Perlstein et al. NEURO-ONCOLOGY
- State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
- (2012) Stella Bernardi et al. Recent Patents on Anti-Cancer Drug Discovery
- Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles
- (2011) Sung Mook Lim et al. BIOMATERIALS
- Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
- (2011) Sungho Bae et al. BIOMATERIALS
- Engineering death receptor ligands for cancer therapy
- (2011) Harald Wajant et al. CANCER LETTERS
- Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
- (2011) Pamela M. Holland CANCER LETTERS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway
- (2011) R Ge et al. CELL DEATH AND DIFFERENTIATION
- Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells
- (2011) N Mazurek et al. CELL DEATH AND DIFFERENTIATION
- miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma
- (2011) Nataliya Razumilava et al. HEPATOLOGY
- Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers
- (2011) Michelle G. Dick et al. INTERNATIONAL JOURNAL OF CANCER
- TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes
- (2011) Liangran Guo et al. JOURNAL OF CONTROLLED RELEASE
- Granulysin Delivered by Cytotoxic Cells Damages Endoplasmic Reticulum and Activates Caspase-7 in Target Cells
- (2011) R. V. Saini et al. JOURNAL OF IMMUNOLOGY
- High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2
- (2011) M.E.D. Chamuleau et al. LEUKEMIA RESEARCH
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Tumor delivery of macromolecular drugs based on the EPR effect
- (2010) Vladimir Torchilin ADVANCED DRUG DELIVERY REVIEWS
- Granzymes in cancer and immunity
- (2010) S P Cullen et al. CELL DEATH AND DIFFERENTIATION
- Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
- (2010) A Morizot et al. CELL DEATH AND DIFFERENTIATION
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
- (2010) Annie Yang et al. CURRENT OPINION IN CELL BIOLOGY
- Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma
- (2010) Bernhard Gillissen et al. JOURNAL OF CELL BIOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- New insights into apoptosis signaling by Apo2L/TRAIL
- (2010) F Gonzalvez et al. ONCOGENE
- miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation
- (2009) Michela Garofalo et al. CANCER CELL
- Down-regulation of c-FLIP Enhances Death of Cancer Cells by Smac Mimetic Compound
- (2009) H. H. Cheung et al. CANCER RESEARCH
- Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
- (2009) Zhaoyu Jin et al. CELL
- Following TRAIL’s path in the immune system
- (2009) Christina Falschlehner et al. IMMUNOLOGY
- Granulysin Induces Cathepsin B Release from Lysosomes of Target Tumor Cells to Attack Mitochondria through Processing of Bid Leading to Necroptosis
- (2009) H. Zhang et al. JOURNAL OF IMMUNOLOGY
- The expression of granulysin in systemic anaplastic large cell lymphoma in childhood
- (2009) Noriko Kitamura et al. LEUKEMIA RESEARCH
- The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation
- (2009) Julián Pardo et al. MICROBES AND INFECTION
- XIAP discriminates between type I and type II FAS-induced apoptosis
- (2009) Philipp J. Jost et al. NATURE
- Genes that mediate breast cancer metastasis to the brain
- (2009) Paula D. Bos et al. NATURE
- Biology and clinical relevance of granulysin
- (2009) A. M. Krensky et al. TISSUE ANTIGENS
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
- (2008) H. Maeda et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development
- (2008) Anne Grosse-Wilde et al. JOURNAL OF CLINICAL INVESTIGATION
- TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
- (2008) Niklas Finnberg et al. JOURNAL OF CLINICAL INVESTIGATION
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
- MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
- (2008) M Garofalo et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started